A prostate-specific membrane antigen-targeting IgG1 monoclonal antibody with a murine origin known as Prostascint is used in imaging procedures.

Indium In-111 capromab pendetide Uses:

• Diagnostic imaging:

  • It is indicated for the diagnostic imaging in patients with:

    • Those with a recent diagnosis of biopsy-proven prostate cancer who have undergone conventional diagnostic testing and are at a high risk of developing pelvic lymph node metastases

    • Patients with postprostatectomy increased PSA levels and negative results from the conventional metastatic evaluation but strong clinical suspicions of metastatic disease

Adult dosage for indium In-111 capromab pendetide:

In diagnostic imaging, the dose of indium In-111 capromab pendetide is:

• 0.5 mg intravenously radiolabeled with respect to 5 mCi of indium 111 chloride
• The dose may be readministered if infiltration or the scan is technically inadequate.

Use in Children:

Not indicated.

Pregnancy Risk Category: N (Not Assigned)

• There have not been any animal reproduction studies.
• It is not recommended to be used by women.

Use during breastfeeding:

• It is not recommended for use by women.

Dose in Kidney disease:

There are no dosage adjustments provided in the manufacturer’s labeling.

Dose in Liver disease:

There are no dosage adjustments provided in the manufacturer’s labeling.

Side Effects of Indium In-111 capromab pendetide Include:

• Immunologic:

  • Antibody development

• Cardiovascular:

  • Hypertension
  • Hypotension

• Hepatic:

  • Increased serum bilirubin

Contraindications to Indium In-111 capromab pendetide:

Allergy reactions to Indium 112 capromab pendetide or other products from murine origin, Indium In111 chloride, or any component of this formulation

Warnings and precautions

• Hypersensitivity

  • Patients can develop anaphylaxis or allergic reactions if they are receiving murine antibody.
  • To treat allergic or anaphylactic reactions, support medications such as adrenaline, hydrocortisone and antiallergic medicine must be readily available at the injection site.

• Anti-human murine antibodies (HAMA).

  • Patients may develop anti-murine antibodies after receiving treatment that could affect the efficacy and effectiveness of murine antibody-based drugs. Further treatment may increase the risk of adverse reactions.
  • It is possible that murine-based products may not be used in the future to diagnose a recurrence. It may also affect some laboratory results.

Indium In-111 capromab pendetide: Drug Interaction

Monitoring parameters:

Monitor for allergic reactions, syncope, and hypotension.

How to administer Indium In-111 capromab pendetide?

• It is to be administered intravenously for about five minutes. The drug should not be mixed with any other medicines.
• The night before the imaging session, a cathartic should be taken, and an hour before each of the 72–120 imaging sessions, a cleansing enema should be used.
• Cathetrize and irrigate the bladder. Following the first infusion of the drug, an imaging session may be done after about 30 minutes.
• The second imaging session may be done 72 to 120 hours after the infusion. The drug should be handled and disposed of appropriately since it is a radiopharmaceutical product.

Mechanism of action of Indium In-111 capromab pendetide:

Capromab pendetide is a monoclonal antibody from the murine IgG1 type directed at the glycoprotein PSMA (Prostate Specific Membrane Antigen) expressed in prostate epithelial cells.

Metabolism:

• Decays by electron capture

Half-life elimination:

• Physical: 67.2 hours;
• Terminal: ~56 to 78 hours

Excretion:

• Urine (10% over 72 hours)

Indium In-111 capromab pendetide Brand Names in Pakistan:

No Brands Available in Pakistan.

International Brand Names of Indium In-111 capromab pendetide:

• ProstaScint